INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is one of the most common lethal malignancies in the United States and China \[[@R1], [@R2]\]. With limitation of useful early diagnostic biomarker and invasiveness of colonoscopy, most of cases are clinical confirmed as TNM II-IV patients, and mid-term patients can benefit from regular surgical operation plus adjuvant chemoradiotherapy. Meanwhile, the therapeutic options against metastatic CRC (mCRC) have expanded with the introduction of anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) and treatment outcomes have improved in the past decade \[[@R3]\].

Cetuximab, a chimeric immunoglobulin 1 monoclonal antibody that targets the extracellular domain of the EGFR, has been validated to be effective in providing clinical benefit in wild-*KRAS* mCRC patients in combination with chemotherapy as first and second lines as well as in monotherapy as third line drug \[[@R3]--[@R7]\]. However, only approximately 10\~20% of patients with chemorefractory mCRC derived good clinical benefit from cetuximab therapy \[[@R8]\], revealing that personalized difference in genetic background might affect individual\'s response and additional mechanisms could lead to CRC progression \[[@R9]\]. Therefore, an understanding of molecular basis of clinical response to cetuximab may be better to identify the subpopulation of patients who are likely to benefit from cetuximab and avoid unnecessary drug toxicity and costs.

The molecular mechanisms underlying response to cetuximab are still substantially unclear; it is that cetuximab acts by means of inhibition of EGFR signal pathway or activation of antibody-dependent cell cytotoxicity (ADCC) \[[@R10]\]. However, only 30\~40% non-responsive patients harbored *KRAS* mutation \[[@R11], [@R12]\], and some *KRAS* mutated patients also showed to respond to cetuximab \[[@R13]\]. These exacting evidences suggested that ADCC might be involved in cetuximab enhanced antitumor efficacy \[[@R13]\]. ADCC is stimulated through the interaction between Fc fragment of lgG1 monoclonal antibodies linked with EGFR of targeted cancer cell and the surface Fc gamma receptor 2a and 3a (FCGR2A and FCGR3A) of IgG carried by immune cells such as natural killer lymphocytes (NK), macrophages and neutrophil, triggering the activation of these immune effective cells and leading to the lysis and death of targeted cancer cell. Genetic variations within *FCGR2A* and *FCGR3A* may contribute to abnormal secondary spatial structure and function of the products, leading to different binding affinity to cetuximab. H131R and V158F are two common single nucleotide polymorphisms (SNPs) which are located in the third and fifth exon of *FCGR2A* and *FCGR3A*, respectively, and two loci appear to be associated with clinical outcome in hematological malignancies and breast cancer with treatment of rituximab and trantuzumab, respectively \[[@R14], [@R15]\]. Follicular lymphoma patients harbored allele V and genotype VV of V158F within *FCGR3A* could benefit from the combination therapy including rituximab \[[@R16]\] and genotype HH of H131R within *FCGR2A* was significantly associated with a shorter event-free survival in breast cancer patients with sequentially given transtuzumab in UNICANCER-PASCO4 trial \[[@R17]\]. Some studies attempted to investigate the role of the two SNPs in treatment efficacy of anti-EGFR mAb in advanced CRC patients, however, these results weren\'t in consistence with each other \[[@R18]--[@R20]\].

In this study, we aimed to investigate the association of *FCGR2A* H131A and *FCGR3A* V158F with clinical outcome of 82 wild-*KRAS* chemorefractory mCRC patients undergoing cetuximab adjuvant therapy. Additionally, a comprehensive meta-analysis including prospective and retrospective studies was carried out to confirm the clinical finding.

RESULT {#s2}
======

Overall, a total of 46 male and 36 female chemorefractory mCRC individuals harbored wide-*KRAS* were included in our study. 52 and 30 were colon and rectal cancer patients, respectively. All of them were TNM-IV stage patients and treated with chemotherapy plus cetuximab. However, only 6 CR, 44 PR, 15 SD and 17 PD were observed in 82 mCRC individuals, respectively. The genotype distributions of H131R within *FCGR2A* and V158F within *FCGR3A* were in Hardy-Weinberg equilibrium (*P* = 0.52 for *FCGR2A*, and *P* = 0.09 for *FCGR3A*, respectively) (Table [1](#T1){ref-type="table"}).

###### Baseline characteristics of 82 mCRC patients treated with adjuvant cetuximab

  Characteristic                     No. of patients   \%
  ---------------------------------- ----------------- ---------------------
  Median and range of age (years)    61 (51--70)       
  Gender                                               
  Male/female                        46/36             56.1%/43.9%
  Location                                             
  Left/right colon/rectal            25/27/30          30.5%/32.9%/36.6%
  Treatment                                            
  Cetuximab + CapeOX                 8                 9.76%
  Cetuximab + CapeOX+AVASTIN         2                 2.43%
  Cetuximab +FOLFIR1                 19                23.17%
  Cetuximab +FOLFIR1+AVASTIN         1                 1.22%
  Cetuximab +FOLFIRI+ Capecitabine   1                 1.22%
  Cetuximab+FOLFOX                   42                51.23%
  Cetuximab+FOLFOX+FOLFIRI           5                 6.10%
  Cetuximab+FOLFOX+AVASTIN           1                 1.22%
  Cetuximab+Tegafur                  1                 1.22%
  Cetuximab+Capecitabine             2                 2.43%
  Tumor response                                       
  CR/PR                              6/44              7.32%/53.66%
  SD/PD                              15/17             18.29%/20.73%
  *FCGR2A* H131R                                       
  HH/HR/RR                           33/44/5           40.24%/53.66%/6.10%
  *FCGR3A* F158V                                       
  FF/FV/VV                           49/25/8           59.76%/30.49%/9.75%

**Abbreviation:** mCRC: metastatic colorectal cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; CapeOX: capecitabine plus oxaliplatin; FOLFIR1: 5-fluorouracil plus calcium folinate plus irinotecan; FOLFOX: 5-fluorouracil plus calcium folinate plus oxaliplatin.

The influence of the two SNPs on the clinical efficacy and survival were described in Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. H131R within *FCGR2A* weren\'t associated with ORR (*P* = 0.542 for HR vs. HH; *P* = 0.357 for RR vs. HH; *P* = 0.454 for HR/RR vs. HH; *P* = 0.598 for RR vs. HH/HR; *P* = 0.710 for HR vs. HH/RR; *P* = 0.409 for R vs. H) and DCR (*P* = 0.644 for HR vs. HH; *P* = 0.461 for RR vs. HH; *P* = 0.559 for HR/RR vs. HH; *P* = 0.527 for RR vs. HH/HR; *P* = 0.787 for HR vs. HH/RR; *P* = 0.510 for R vs. H) in co-dominant, dominant, recessive, over-dominant and allele genetic models, respectively. No statistical significant difference in response to cetuximab based therapy (*P* = 0.425 for FV vs. FF; *P* = 0.835 for VV vs. FF; *P* = 0.454 for FV/VV vs. FF; *P* = 0.967 for VV vs. FF/FV; *P* = 0.441 for FV vs. FF/VV; *P* = 0.535 for V vs. F) or DCR (*P* = 0.463 for FV vs. FF; *P* = 0.957 for VV vs. FF; *P* = 0.559 for FV/VV vs. FF; *P* = 1.000 for VV vs. FF/FV; *P* = 0.446 for FV vs. FF/VV; *P* = 0.718 for V vs. F) based on *FCGR3A* V158F was observed. Also, there was no significant association between *FCGR* combined genotype and ORR (*P* = 0.642 for RR or VV vs. H and F) and DCR (*P* = 0.554 for RR or VV vs. H and F) in present study.

###### Clinical response of wild-*KRAS* mCRC patients treated with adjuvant cetuximab according to *FCGR2A* and *FCGR3A* polymorphisms

  Genetic Model   Polymorphism          No. of patients   Objective response   Disease control                                                              
  --------------- --------------------- ----------------- -------------------- ----------------- ------------------------------------------ ------- ------- ------------------------------------------
                  ***FCGR2A* H131R**                      No.                  No.                                                          No.     No.     
  Co-dominant     HR vs. HH             44/33             12/7                 32/26             0.542                                      21/14   23/19   0.644
                  RR vs. HH             5/33              2/7                  3/26              0.357[\*](#tfn_001){ref-type="table-fn"}   3/14    2/−19   0.461[\*](#tfn_001){ref-type="table-fn"}
  Dominant        HR/RR vs. HH          49/33             14/7                 35/26             0.454                                      24/14   25/19   0.559
  Recessive       RR vs. HH/HR          5/77              2/19                 3/58              0.598[\*](#tfn_001){ref-type="table-fn"}   3/35    2/42    0.527[\*](#tfn_001){ref-type="table-fn"}
  Over-dominant   HR vs. HH/RR          44/38             12/9                 32/29             0.71                                       21/17   23/21   0.787
  Allele          R vs. H               54 /110           16/26                38/84             0.409                                      27/49   27/61   0.51
                  ***FCGR3A* F158V**                                                                                                                        
  Co-dominant     FV vs. FF             25/49             5/14                 20/35             0.425                                      10/24   15/25   0.463
                  VV vs. FF             8/49              2/14                 6/35              0.835[\*](#tfn_001){ref-type="table-fn"}   4/24    4/25    0.957[\*](#tfn_001){ref-type="table-fn"}
  Dominant        FV/VV vs. FF          33/49             7/14                 26/35             0.454                                      14/24   19/25   0.559
  Recessive       VV vs. FF/FV          8/74              2/19                 6/55              0.967[\*](#tfn_001){ref-type="table-fn"}   4/34    4/40    1.000[\*](#tfn_001){ref-type="table-fn"}
  Over-dominant   FV vs. FF/VV          25/57             5/16                 20/41             0.441                                      10/28   15/29   0.446
  Allele          V vs. F               41/123            9/33                 32/90             0.535                                      18/58   23/65   0.718
                  ***FCGR* combined**                                                                                                                       
                  H and F vs RR or VV   69/13             17/4                 52/9              0.642                                      31/7    38/6    0.554

**Abbreviation:** mCRC: metastatic colorectal cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease. *P*-value: result of chi-square test;

*P*-value: result of fisher\'s exact test.

###### The polymorphisms of *FCGR2A* and *FCGR3A* and clinical survival of 82 wild-*KRAS* mCRC patients treated with adjuvant cetuximab

  Model                 Locus          Progression-free survival   Overall survival                                                                                                                       
  --------------------- -------------- --------------------------- ----------------------- ------- ------------- ------------- -------------------------- ------------------------- ------- ------------- -------------
  ***FCGR2A* H131R**                                                                                                                                                                                      
  Co-dominant           HR vs. HH      7/5.5                       5.22−8.78/1.27−9.73     0.937   1.086         0.636−1.856   13/13                      10.54−15.46/8.43−17.57    0.642   1.332         0.765−2.318
                        RR vs. HH      6/5.5                       3.52−8.48/1.27−9.73     0.675   0.608         0.203−1.816   13/13                      11.76−14.24/8.43−17.57    0.247   1.341         0.474−3.797
  Dominant              HR/RR vs. HH   6/5.5                       5.19−6.81/1.27−9.73     0.996   1.02          0.608-1.713   13/13                      11.80−14.20/8.43−17.57    0.49    1.329         0.779−2.269
  Recessive             RR vs. HR/HH   6/6                         3.52−8.48/5.16−6.84     0.586   0.636         0.223−1.815   13/13                      11.76−14.24/11.66−14.34   0.249   1.233         0.475−3.203
  Over-dominant         HR vs. HH+RR   7/6                         5.22−8.78/4.83−7.17     0.824   1.162         0.687−1.964   13/13                      10.54−15.46/12.24−13.77   0.866   1.239         0.726−2.113
  Allele                R vs. H        6/6                         4.72−7.28/4.38−7.62     0.86    0.989         0.733−1.333   13/13                      11.18−14.82/10.58−15.42   0.357   1.191         0.870−1.631
  ***FCGR3A* V158F**                                                                                                                                                                                      
  Co-dominant           FV vs. FF      6/8                         4.62−7.39/4.78−11.23    0.619   0.845         0.453−1.577   14.5/14                    10.21−18.79/11.04−16.96   0.777   1.002         0.472−2.127
                        VV vs. FF      5.5/8                       0.00−11.04/4.78−11.23   0.933   0.936         0.406−2.159   12/14                      2.50−21.50/11.04−16.96    0.815   0.828         0.344−1.996
  Dominant              FV/VV vs. FF   6/8                         4.38−7.62/4.78−11.23    0.69    0.801         0.470−1.365   14.5/14                    9.39−19.61/11.04−16.96    0.724   0.901         0.495−1.642
  Recessive             VV vs. FF/FV   5.5/7                       0.00−11.04/4.54−9.46    0.852   0.839         0.375−1.877   12/14                      2.50−21.50/10.98−17.02    0.698   0.797         0.349−1.819
  Over-dominant         FV vs. FF/VV   6/8                         4.62−7.39/5.26−10.74    0.768   0.861         0.469−1.581   14.5/14                    10.21−18.79/11.78−16.22   0.914   1.06          0.515−2.184
  Allele                V vs. F        6/8                         4.18−7.83/5.68−10.32    0.682   0.862         0.581−1.278   14.5/14                    8.68−20.32/11.87−16.13    0.632   0.888         0.585−1.349
  ***FCGR* combined**                                                                                                                                                                                     
  H and F vs RR or VV   6/9            3.92−8.08/ 6.87−11.13       0.398                   0.798   0.364−1.750   13/15         10.21−15.79/ 12.51−17.49   0.903                     0.823   0.360−1.878   

**Abbreviation:** mCRC: metastatic colorectal cancer;

*P*-value: Result of log-rank test of Kaplan-Meier curve;

HR: hazard ratio adjusted by sex, age, smoking, drinking and status of diabetes and hypertension; CI: confidential interval.

The median PFS of cases harbored allele R and H within H131R of *FCGR2A* were 6.0 and 6.0 months, and 5.5, 7.0, 6.0, 6.0, 6.0, 6.0 months for genotype HH, HR, RR, HR/RR, HH/HR, HH/RR of *FCGR2A*, respectively. However, H131R wasn\'t associated with PFS in co-dominant (HR = 1.086, 95%CI = 0.636--1.856 for HR vs. HH; HR = 0.608, 95%CI = 0.203--1.816 for RR vs. HH), dominant (HR = 1.02, 95%CI = 0.608--1.713), recessive (HR = 0.636, 95%CI = 0.223--1.815), over-dominant (HR = 1.162, 95%CI = 0.687--1.964) and allele (HR = 0.989, 95%CI = 0.733--1.333) models. The median OS of cases carrying H131R genotypes and alleles was 13 months, and there was no significant difference in OS in comparison of HR vs. HH (HR = 1.332, 95%CI = 0.765--2.318), RR vs. HH (HR = 1.341, 95%CI = 0.474--3.797), HR/RR vs. HH (HR = 1.329, 95%CI = 0.779--2.269), RR vs. HR/HH (HR = 1.233, 95%CI = 0.475--3.203), HR vs. HH/RR (HR = 1.239, 95%CI = 0.726--2.113), allele R vs. H (HR = 1.191, 95%CI = 0.870--1.631), respectively. Patient harbored genotype FV (HR = 0.845, 95%CI = 0.453--1.577 for PFS, HR = 1.002, 95%CI = 0.472--2.127 for OS), VV (HR = 0.936, 95%CI = 0.406--2.159 for PFS, HR = 0.828, 95%CI = 0.344--1.996 for OS) and FV/VV (HR = 0.801, 95%CI = 0.470--1.365 for PFS, HR = 0.901, 95%CI = 0.495--1.642 for OS) of V158F within *FCGR3A* were not shown a statistically longer or shorter PFS and OS than those individuals harbored genotype FF, respectively, no significant association was observed in recessive (HR = 0.839, 95%CI = 0.375--1.877 for PFS; HR = 0.797, 95%CI = 0.349--1.819 for OS), over-dominant (HR = 0.861, 95%CI = 0.469--1.581 for PFS; HR = 1.06, 95%CI = 0.515--2.184 for OS), allele (HR = 0.862, 95%CI = 0.581--1.278 for PFS; HR = 0.888, 95%CI = 0.585--1.349 for OS) models. Meanwhile, PFS (HR = 0.798, 95%CI = 0.364--1.750) and OS (HR = 0.823, 95%CI = 0.360--1.878) of the cases harbored genotype RR or VV weren\'t shown significant difference when compared to cases with allele H and F (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

![Kaplan-Meier curves for *FCGR2A* H131R and *FCGR3A* V158F for progression-free survival and overall survival\
**A.** H131R for PFS; **B.** V158F for PFS; **C.** H131R for OS; **D.** V158F for OS.](oncotarget-06-28071-g001){#F1}

A total of 14 published articles (15 eligible studies) and our study were included in this comprehensive meta-analysis to further evaluate the association of *FCGR2A* and *FCGR3A* polymorphisms with clinical outcome in advanced CRC patients undergoing anti-EGFR mAb based therapy \[[@R18]--[@R31]\]. The baseline characteristics of included studies and the results of heterogeneity test, odds ratio (OR), median survival ratio (MSR) and corresponding 95% confidential interval (95%CI) were reported in [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and Table [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. As shown from Table [4](#T4){ref-type="table"}, Genotypes of H131R weren\'t associated with clinical outcome of overall and *KRAS* wild chemorefractory mCRC patients in terms of ORR, DCR in co-dominant, dominant, recessive, over-dominant, allele models, PFS and OS in co-dominant and dominant models. No significant difference was observed between ORR or DCR and genotypes and alleles of V158F, whatever the *KRAS* status. However, genotype FV/VV within V158F of *FCGR3A* was observed to be significant associated with a shorter PFS in overall (MSR = 0.680, 95%CI = 0.549--0.842) and *KRAS* wild population patients (MSR = 0.728, 95%CI = 0.648--0.818), and individuals harbored genotype FF showed a longer OS than those carrying genotype VV of *FCGR3A* V158F only in overall population (MSR = 0.733, 95%CI = 0.578--0.930) (Table [5](#T5){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). There was no significant publication bias in all comparisons between genotypes of H131R and V158F and clinical response and outcome, respectively.

###### Meta-analysis results of the association between *FCGR2A* H131R, *FCGR3A* F158V polymorphisms and clinical response of mCRC patients with adjuvant anti-EGFR mAb therapy

  Population            Model           Comparison         ORR    DCR                                          
  --------------------- --------------- ------------------ ------ ------- --------------------- ------ ------- ------------------------
  ***FCGR2A* H131R**                                                                                           
  **Overall**           Co-dominant     HR vs. HH          738    0.456   1.136(0.815--1.584)   297    0.987   1.244(0.732--2.112)
                                        RR vs. HH          463    0.234   1.308(0.852--2.009)   185    0.077   1.035(0.307--3.495)
                        Dominant        HR/RR vs. HH       1857   0.389   1.156(0.919--1.453)   1333   0.307   0.993(0.780--1.265)
                        Recessive       RR vs.HR/RR        933    0.283   1.269(0.908--1.773)   370    0.057   0.883(0.285--2.732)
                        Over-dominant   HR vs. HH/RR       904    0.358   0.993(0.744--1.325)   370    0.79    1.242(0.805--1.916)
                        Allele          R vs. H            1808   0.116   1.180(0.959--1.452)   740    0.002   0.780(0.414--1.471)
  ***KRAS* wild**       Co-dominant     HR vs. HH          393    0.391   1.234(0.831--1.835)   123    0.941   1.459(0.782--2.722)
                                        RR vs. HH          246    0.184   1.234(0.771--1.974)   74     0.178   1.623(0.646--4.076)
                        Dominant        HR/RR vs. HH       1110   0.316   1.247(0.960--1.619)   790    0.671   1.115(0.819--1.518)
                        Recessive       RR vs.HR/HH        500    0.14    1.193(0.752--1.892)   151    0.096   1.175(0.291--4.748)
                        Over-dominant   HR vs. HH/RR       471    0.175   1.079(0.740--1.571)   151    0.422   1.323(0.622--2.815)
                        Allele          R vs. H            942    0.043   1.10(0.692--1.748)    302    0.084   1.304(0.765--2.224)
  ***FCGR3A* V158F**                                                                                           
  **Overall**           Co-dominant     FV vs. FF          834    0.583   0.805(0.592−1.096)    283    0.15    0.937(0.567--1.550)
                                        VV vs. FF          561    0.644   0.881(0.565--1.375)   193    0.007   1.311(0.292--5.897)
                        Dominant        FV/VV vs. FF       1026   0.113   0.880(0.667--1.162)   383    0.038   0.916(0.576--1.458)
                        Recessive       VV vs. FV/FF       1983   0.874   0.987(0.743--1.311)   1331   0.041   0.897(0.407--1.973)
                        Over-dominant   FV vs. FF/VV       977    0.735   0.855(0.643--1.138)   339    0.752   0.549--1.390
                        Allele          V vs. F            1954   0.351   0.866(0.702--1.068)   678    0.013   1.019(0.541--1.919)
  ***KRAS* wild**       Co-dominant     FV vs. FF          404    0.61    0.851(0.572--1.266)   119    0.052   0.898(0.269--2.992)
                                        VV vs. FF          266    0.935   1.153(0.640--2.077)   81     0.072   1.302(0.286--5.940)
                        Dominant        FV/VV vs. FF       471    0.605   0.889(0.614--1.287)   154    0.024   0.987(0.284--3.429)
                        Recessive       VV vs. FV/FF       1154   0.961   1.089(0.779--1.522)   815    0.283   0.710(0.483--1.043)
                        Over-dominant   FV vs. FF/VV       471    0.528   0.887(0.602--1.306)   154    0.268   0.708(0.332--1.511)
                        Allele          V vs. F            942    0.707   0.987(0.744--1.311)   308    0.033   1.121(0.403--3.119)
  ***FCGR* combined**                                                                                          
  **Overall**                           HH or VV vs. R/F   160    0.126   1.698(0.762--3.784)   160    0.107   1.012(0.524--1.955)
                                        RR or VV vs. H/F   115    0.787   0.684(0.210--2.222)   115    0.001   4.103 (0.108--156.599)

**Abbreviation:** mCRC: metastatic colorectal cancer; *P*~h~: result of heterogeneity test; ORR: objective response rate; DCR: disease control rate; OR: odds ratio; CI: confidential interval;

###### Meta-analysis results of the association of *FCGR2A* H131R, *FCGR3A* F158V polymorphisms and clinical survival of mCRC patients with adjuvant anti-EGFR mAb therapy

  Population           Model          Comparison     PFS    OS                                                    
  -------------------- -------------- -------------- ------ --------- -------------------------- ------ --------- --------------------------
  ***FCGR2A* H131R**                                                                                              
  **Overall**          Co-dominant    HR vs. HH      739    \<0.001   1.111 (0.909--1.358)       573    \<0.001   1.156 (0.929--1.438)
                                      RR vs. HH      466    \<0.001   0.936 (0.704--1.244)       364    \<0.001   0.864 (0.616--1.212)
                       Dominant       HR/RR vs. HH   1363   \<0.001   0.993 (0.782--1.262)       1176   0.822     0.946 (0.894--1.002)
  ***KRAS* wild**      Co-dominant    HR vs. HH      471    \<0.001   1.092 (0.892--1.338)       348    0.062     1.116 (0.942--1.323)
                                      RR vs. HH      285    0.015     0.953 (0.783--1.159)       210    0.818     0.933 (0.815--1.068)
                       Dominant       HR/RR vs. HH   980    \<0.001   0.974 (0.778--1.220)       821    0.044     1.056 (0.890--1.253)
  ***FCGR3A* V158F**                                                                                              
  **Overall**          Co--dominant   FV vs. FF      789    \<0.001   0.943 (0.767--1.159)       617    \<0.001   1.094 (0.907--1.320)
                                      VV vs. FF      514    \<0.001   0.896 (0.679--1.181)       405    \<0.001   **0.733 (0.578--0.930)**
                       Dominant       FV/VV vs. FF   311    0.027     **0.680 (0.549--0.842)**          \-        \-
                       Recessive      VV vs. FV/FF   1077   \<0.001   1.292 (0.480--3.479)              \-        \-
  ***KRAS* wild**      Co-dominant    FV vs. FF      478    \<0.001   1.054 (0.872--1.275)       360    \<0.001   1.128 (0.842--1.510)
                                      VV vs. FF      323    \<0.001   1.061 (0.733--1.536)       244    \<0.001   0.766 (0.521--1.126)
                       Dominant       FV/VV vs. FF   283    0.12      **0.728 (0.648--0.818)**          \-        \-
                       Recessive      VV vs. FV/FF   712    \<0.001   1.382 (0.612--3.12)               \-        \-

**Abbreviation:** mCRC: metastatic colorectal cancer; *P*~h~: result of heterogeneity test; PFS: progression-free survival; OS: overall survival; MSR: median survival ratio; 95%CI: 95% confidential interval.

![Meta-analysis result of association between *FCGR3A* V158F and progression-free survival and overall survival in mCRC patients treated with anti-EGFR mAb based therapy\
**A.** FV/VV vs. FF for PFS in overall population; **B.** FV/VV vs. FF for PFS in *KRAS* wild population; **C.** VV vs. FF for OS in overall population.](oncotarget-06-28071-g002){#F2}

DISCUSSION {#s3}
==========

This study, to the best of our knowledge, is the first report that combined a retrospective study and a comprehensive meta-analysis with the largest sample size for estimating the association between *FCGR2A* H131R and *FCGR3A* V158F and clinical outcome of mCRC patients with treatment of anti-EGFR mAb based therapy. With limitation of small sample size, our retrospective study showed no significant association between *FCGR2A* and *FCGR3A* polymorphisms and clinical outcome in 82 wild-*KRAS* chemorefractory mCRC individuals treated with chemotherapy plus cetuximab. However, the robust results of meta-analysis showed that genotype FF within V158F was significant associated with a longer PFS and OS than FV/VV and VV genotype in overall and *KRAS* wild population, respectively. These findings suggested that *KRAS* wild chemorefractory mCRC individual harbored genotype FF of V158F could benefit from anti-EGFR mAb based therapy in terms of PFS and OS, and the genotype could be used as a genetic biomarker to predict clinical prognosis of wild-*KRAS* mCRC patients with adjuvant treatment of anti-EGFR mAb.

ADCC is considered as an important mechanism for the antitumor effect of anti-EGFR mAb in mCRC patients \[[@R13], [@R32]\]. Cetuximab, an IgG1 monoclonal antibodies, can bind with EGFR protein of tumor cell by its Fab fragment, and its Fc fragment engages FCGR on an immune cell to activate the process of ADCC, eventually resulting in attacking and eliminating the cetuximab-coated tumor cell. Alternation of amino acid at specific binding-domain of Fc fragment of IgG can affected FCGR2A and FCGR3A binding affinity *in vitro* and *in vivo* \[[@R33]--[@R35]\]. H131A and V158F are located at the extracellular ligand-specific binding domain of *FCGR2A* and *FCGR3A*, respectively. *FCGR2A*-H allele and *FCGR3A*-V allele and VV genotype were associated with higher affinity to lgG2, lgG1 and lgG3 than others \[[@R35]--[@R37]\], respectively. Thus, the two common polymorphisms within *FCGR2A* and *FCGR3A* affected their receptor\'s specific binding-domain of IgG, leading to different antitumor effect in mCRC patients with anti-EGFR mAb based therapy.

Several studies concerning *FCGR* polymorphisms and efficacy of trantuumab and rituximab demonstrated that *FCGR2A* H131R and *FCGR3A* V158F could predict clinical efficacy and survival of patients with breast cancer and lymphoma, respectively \[[@R17], [@R38]\]. Cohort study concerned mCRC supported the hypothesis that *FCGR2A* H131R and *FCGR3A* V158F were associated with clinical outcome of mCRC patients with cetuximab in a small sample size \[[@R30]\]. Whereas, a large cohort study containing 1123 chemorefractory mCRC patients failed to support the significant results \[[@R18]\]. In our retrospective study, we didn\'t observe the significant association between *FCGR2A* H131R and *FCGR3A* V158F and clinical outcome in chemotherapy plus cetuximab treated mCRC patients in terms of ORR, DCR, PFS and OS in retrospective study. Moreover, H131R within *FCGR2A* wasn\'t associated with ORR, DCR, PFS and OS in overall and *KRAS* wild subgroups in the meta-analysis, indicating that the polymorphism of *FCGR2A* might be not involved in anti-EGFR mAb induced ADCC effect and it could not predict clinical outcome of cetuximab based therapy in wild-*KRAS* mCRC patients. Nonetheless, V158F within *FCGR3A* was significantly associated with PFS in dominant genetic model in overall and *KRAS* wild populations and genotype VV of the loci was significantly associated with a shorter OS in overall population in the meta-analysis. These findings suggested that V158F of *FCGR3A* was involved in clinical survival of anti-EGFR mAb treated mCRC individual, and genotype FF could be used as a prognostic biomarker to predict survival of anti-EGFR mAb treated mCRC patients in overall population, especially *KRAS* wild carrier. Our finding is in agreement with previous studies conducted by Zhang et al and Pander et al \[[@R25], [@R30]\], respectively, but against our speculation and inconsistent with the results of other studies \[[@R18], [@R19], [@R23]\].

The possible reason why genotype FF of V158F within *FCGR3A* was associated a longer PFS and OS compared with genotype VV and VV/VF remains partly understand. Included individuals in our retrospective study and eligible studies in meta-analysis were all chemorefractory mCRC patients, and long-time\'s regular chemoradiotherapy and increasing burden of CRC leaded to a gradual decreased immunologic surveillance \[[@R18], [@R26]\]. NK cell was generally scarce within CRC tumor tissues, on the contrary, normal level of NK cell was examined in adjacent normal mucosa \[[@R39]\]. Meanwhile, a significant reduction in the percentage of NKG2D+NK cell was observed in peripheral blood of metastatic colon cancer patients \[[@R40]\]. Additionally, tumor-associated macrophage (TAM) is one of the most frequently found immune cells in the tumor microenvironment \[[@R41]\]. Although genotype VV of V158F displayed a significant higher anti-EGFR mAb-triggered ADCC in peripheral blood mononuclear cells *in vitro* \[[@R23]\]. However, a possible mechanism is that the high-affinity allele V of V158F within *FCGR3A* might contribute to decreased ADCC-triggered by NK cell \[[@R18], [@R26]\], but through cross-linking of the FCGR to increase activation of TAM in tumor microenvironment by anti-EGFR mAb. Activated TAM releases large amounts of pro-angiogentic and pro-metastatic regulators to facilitate angiopoiesis, matrix breakdown, tumor cell motility and promote tumor growth, leading to poor prognosis \[[@R41], [@R42]\].

In conclusion, we fail to find the significant association between *FCGR2A* H131R and clinical outcome in *KRAS* wild mCRC individuals with adjuvant cetuximab therapy, but *KRAS* wild chemorefractory mCRC individual harbored genotype FF of V158F can benefit from cetuximab based therapy in terms of PFS and OS, and it may be a prognostic factor to evaluate the clinical survival of wild-*KRAS* mCRC patients undergoing anti-EGFR mAb therapy. With limitation of the study, multi-central, well designed prospective studies with large sample size are warrant to further validate our findings.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Patients with mCRC who diagnosed and treated in Nanjing First Hospital and Pingxiang People\'s Hospital between 2007 May and 2014 December were enrolled in our retrospective study. All of them were histologically proven TNM-IV stage and harbored with wild-*KRAS*. The included individuals were treated with cetuximab plus conventional chemotherapy regimen such as CapeOX, FOLFIR1 and FOLFOX. Cetuximab was used 400mg/m^2^ dose at first, then 250mg/m^2^ subsequently, 21 day a cycle, and treated until cancer progression or unacceptable toxicity. This study was approved by the Institution Ethics Commission of Southeast University, and all included participants were signed informed consents.

Efficacy evaluation and following-up {#s4_2}
------------------------------------

In accordance with the Response Evaluation Criteria In Solid Tumors Criteria 1.0 (RECST 1.0), the cancer response to cetuximab therapy was evaluated every month at the time of hospitalization and the evaluated results were defined as complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD), respectively. Progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) and disease control rate (DCR) were used as endpoints in our study. PFS and OS were calculated from the first date of cetuximab usage to the time of disease progression and death, respectively. Relevant data (sex, age, treatment, *KRAS* status, and response evaluated results) were collected from the cases\' medical records.

PCR amplification and genotyping {#s4_3}
--------------------------------

Human genomic DNA was extracted from paraffin-embedded CRC tissues or EDTA anti-coagulated peripheral blood samples using TIANamp Genomic DNA Kit (TIANGEN, Beijing, China) and stored at −80°C till detection. Taqman-genotyping real-time PCR were selected to detect genotypes of *FCGR2A* H131R and *FCGR3A* V158F using ABI7500 fluorescence quantitative PCR system (Applied Biosystems, Foster City, USA). The detail probe, primer sequence, PCR protocol and detection were in accordance to the study reported by Norton et al \[[@R38]\].

Meta-analysis {#s4_4}
-------------

In order to enhance statistical power of the study, a meta-analysis including all eligible studies was conducted to further confirm our results. Relevant article was screened in the Pubmed, Web of SCI and Wanfang databases in English and Chinese using search terms of "*FCGR2A/3A* and cetuximab or CRC", "rs1801274/rs396991 and cetuximab or CRC", and " H131R/V158F and cetuximab or CRC" dating end up to March of 2015. In addition, a manual searching in reference of relevant articles was carried out to obtain substantial studies. Relevant articles were identified as eligible study in accordance with following including criteria: (1) retrospective or prospective study was concerned *FCGR2A/3A* polymorphisms and clinical outcome of chemorefractory mCRC cases treated with adjuvant cetuximab"; (2) efficacy evaluation criteria was in accordance with RECST 1.0/1.1; (3) studies provided median survival time, number of cases, genotype distributions, ORR, DCR. On the contrary, review, correspondence, letter, meta-analysis, case report or studies without providing relevant data were excluded from the study. Relevant study search, eligible study identification, data extraction and statistics were conducted by two independent investigator (Hou-Qun Ying and Feng Wang) and any discrepancies were discussed to reach consensus or made final decision by the third investigator (Xiao-Lin Chen).

Statistical analysis {#s4_5}
--------------------

The genotype frequencies of *FCGR2A* H131R and *FCGR3A* V158F in all cases were calculated by counting. Pearson χ^2^ test was selected to evaluate association between the loci genotypes and response to cetuximab based treatment, and *P* \< 0.05 were considered statistically significance. Kaplan-Meier curve with log-rank test and backward elimination multivariate Cox regression analysis were used to determine the influence of the *FCGR2A* and *FCGR3A* polymorphisms on PFS and OS, and the significant *P*-value was set at 0.05. Q test and estimated I^2^ were used to assess the heterogeneity between eligible studies, and *P*~h~ \< 0.1 or I^2^ \> 50% was considered as exist of significant heterogeneity. Overall effect of the meta-analysis was evaluated using Z test in the fixed model (*P*~h~ \> 0.1) or the random model (*P*~h~ \< 0.1) according to the heterogeneity test and *P*~z~ \< 0.05 showed a statistical significance. Begg\'s funnel plot was selected to estimate the possible publication bias, and asymmetric funnel plot was considered as the existence of publication bias. All statistical analyses were performed using the SPSS statistical 17.0 (SPSS Inc., Chicago, IL) and Stata 11.0 software (Stata Corporation, College Station, TX).
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